Drug Profile


Alternative Names: FCPEC; RX 3117

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Antineoplastics; Nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; Apoptosis stimulants; CDC2 protein kinase inhibitors; Cell division inhibitors; DNA cytosine 5 methyltransferase 1 inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Phase I/II Bladder cancer
  • Phase I Solid tumours

Most Recent Events

  • 14 Aug 2017 Rexahn Pharmaceuticals plans a clinical trial for Bladder cancer (Metastatic disease, Combination therapy) in 2017
  • 14 Aug 2017 Rexahn Pharmaceuticals plans a phase I/II trial for Pancreatic cancer (First-line therapy, Metastatic disease) in USA (NCT03189914)
  • 10 Jul 2017 Rexahn Pharmaceuticals receives patent allowance for fluorocyclopentenylcytosine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top